Wells Fargo’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-37,955
| Closed | -$364K | – | 7371 |
|
|
2024
Q4 | $364K | Buy |
37,955
+6,870
| +22% | +$35.8K | ﹤0.01% | 4399 |
|
|
2024
Q3 | $88.9K | Buy |
31,085
+3,252
| +12% | +$10.1K | ﹤0.01% | 5086 |
|
|
2024
Q2 | $81.3K | Buy |
27,833
+3,803
| +16% | +$10.4K | ﹤0.01% | 5063 |
|
|
2024
Q1 | $76.7K | Buy |
24,030
+3,084
| +15% | +$10.3K | ﹤0.01% | 5052 |
|
|
2023
Q4 | $70.4K | Buy |
20,946
+4,135
| +25% | +$10.7K | ﹤0.01% | 5114 |
|
|
2023
Q3 | $40K | Sell |
16,811
-8,970
| -35% | -$18.8K | ﹤0.01% | 5299 |
|
|
2023
Q2 | $45.4K | Buy |
25,781
+25,424
| +7,122% | +$64.9K | ﹤0.01% | 5460 |
|
|
2023
Q1 | $1.1K | Sell |
357
-13,994
| -98% | -$83.9K | ﹤0.01% | 6353 |
|
|
2022
Q4 | $76.1K | Buy |
14,351
+21
| +0.1% | +$96 | ﹤0.01% | 4679 |
|
|
2022
Q3 | $50K | Buy |
14,330
+129
| +0.9% | +$427 | ﹤0.01% | 4958 |
|
|
2022
Q2 | $37K | Buy |
14,201
+75
| +0.5% | +$209 | ﹤0.01% | 5170 |
|
|
2022
Q1 | $64K | Sell |
14,126
-32,172
| -69% | -$145K | ﹤0.01% | 5536 |
|
|
2021
Q4 | $315K | Buy |
46,298
+46,166
| +34,974% | +$314K | ﹤0.01% | 5011 |
|
|
2021
Q3 | $1K | Hold |
132
| – | – | ﹤0.01% | 6828 |
|
|
2021
Q2 | $1K | Sell |
132
-4,634
| -97% | -$41.5K | ﹤0.01% | 6769 |
|
|
2021
Q1 | $46K | Buy |
4,766
+3,318
| +229% | +$32.5K | ﹤0.01% | 5852 |
|
|
2020
Q4 | $16K | Sell |
1,448
-2,718
| -65% | -$28.7K | ﹤0.01% | 5918 |
|
|
2020
Q3 | $37K | Buy |
+4,166
| New | +$47.4K | ﹤0.01% | 5610 |
|
Other funds holding PSTX
Wells Fargo's PSTX Position: Q1 2025 in Review
Wells Fargo sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 37,955 shares — an estimated $364K sold.
Wells Fargo first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $364K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Wells Fargo reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Wells Fargo sold 37,955 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $364K.
- Wells Fargo first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Wells Fargo's Poseida Therapeutics, Inc. Common Stock position peaked at $364K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.